Evaluation of nanoparticle tracking analysis for total virus particle determination

Virology Journal

Volumn 9, Issue , 2012, Pages

  Kramberger, Petra ^a,b   Ciringer, Mateja ^b   Trancar, Ale ^a,b   Peterka, Matja ^a,b  

^a BIA SEPARATIONS D O O   (Slovenia)

^b Instrumentation and Process Control   (Slovenia)

Author keywords

Adenovirus 5; CIM monolithic column; Influenza; Latex particles; NanoSight; NTA

Indexed keywords

LATEX; NANOPARTICLE;

ACCURACY; ADENOVIRUS 5; ARTICLE; CHROMATOGRAPHY; COMPUTER PROGRAM; CONCENTRATION (PARAMETERS); DILUTION; HEMAGGLUTINATION; INFLUENZA VIRUS; NONHUMAN; PARTICLE SIZE; VIRUS PURIFICATION;

ADENOVIRIDAE; NANOPARTICLES; ORTHOMYXOVIRIDAE; REPRODUCIBILITY OF RESULTS; SOFTWARE; VIRAL LOAD; VIRION;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; ORTHOMYXOVIRIDAE;

EID: 84868641569     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-265     Document Type: Article

References (27)

1. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Kistner O, Howard MK, Spruth M, Wodal W, Brühl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I, Tauer C, Grillberger L, Mundt W, Falkner FG, Barrett PN, Vaccine 2007 25 32 6028 6036 10.1016/j.vaccine.2007.05.013 17614165 (Pubitemid 47077543)
2. M2e-based universal influenza A vaccine. Fiers W, Filette MD, Bakkouri KE, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X, Vaccine 2009 27 45 6280 6283 10.1016/j.vaccine.2009.07.007 19840661
3. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Ru AL, Jacob D, Transfiguracion J, Ansorgea S, Henry O, Kamena AA, Vaccine 2010 28 3661 3671 10.1016/j.vaccine.2010.03.029 20347632
4. Characterization and quality control of recombinant adenovirus vectors for gene therapy. Roitsch C, Achstetter T, Benchaibi M, Bonfils E, Cauet G, Gloeckler R, Lhôte H, Keppi E, Nguyen M, Spehner D, Dorsselaer AV, Malarme D, J Chromatogr B 2001 752 2 263 280 10.1016/S0378-4347(00)00557-0 (Pubitemid 32168161)
5. Targeted gene therapy toward astrocytoma using a Cre/loxP-based adenovirus system. Maeda M, Namikawa K, Kobayashi I, Ohba N, Takahara Y, Kadono T, Anaka A, Kiyama H, Brain Res 2006 1081 1 34 43 10.1016/j.brainres.2006.01.105 16529724
6. Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. Hartman ZC, Appledorn DM, Amalfitano A, Virus Res 2008 132 1-2 1 14 18036698 (Pubitemid 351232078)
7. Production of adenovirus vector for gene therapy. Nadeau I, Kamen A, Biotechnol Adv 2003 20 7-8 475 489 14550017 (Pubitemid 36010677)
8. My enemy's enemy is my friend: Using phages to fight bacteria. Bradbury J, Lancet 2004 363 624 625 10.1016/S0140-6736(04)15629-8 14989277 (Pubitemid 38264183)
9. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Clark JR, March JB, Trends Biotechnol 2006 24 212 218 10.1016/j.tibtech.2006.03.003 16567009
10. Preventing biofilms of clinically relevant organisms using bacteriophage. Donlan RM, Trends Microbiol 2009 17 66 72 10.1016/j.tim.2008.11.002 19162482
11. Bacterial viruses against viruses pathogenic for man? Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Gorski A, Virus Res 2005 110 1 8 10.1016/j.virusres.2005.01.009 15845250 (Pubitemid 40544541)
12. Biophysical characterization of influenza virus subpopulations using field flow fractionation and multiangle light scattering: Correlation of particle counts, size distribution and infectivity. Wei Z, Mcevoy M, Razinkov V, Polozova A, Li E, Casas-Finet J, Tous GI, Balu P, Pan AA, Mehta H, Schenerman MA, J Virol Methods 2007 144 1-2 122 132 17586059 (Pubitemid 47095043)
13. Aggregation of influenza virus ribonucleocapsids at low pH. Zoueva OP, Bailly JE, Nicholls R, Brown EG, Virus Res 2002 85 2 141 149 10.1016/S0168-1702(02)00028-X 12034481 (Pubitemid 34606909)
14. Identification of Factors that Contribute to Recombinant AAV2 Particle Aggregation and Methods to Prevent Its Occurrence during Vector Purification and Formulation. Wright JF, Le T, Prado J, Bahr-Davidson J, Smith PH, Zhen Z, Sommer JM, Pierce GF, Qu G, Mol Ther 2005 12 1 171 178 10.1016/j.ymthe.2005.02. 021 15963933 (Pubitemid 40862369)
15. Comparative thermal stabilities of recombinant adenoviruses and hexon protein. Ihnat PM, Vellekamp G, Obenauer-Kutner LJ, Duan J, Han MA, Witchey-Lakshmanan LC, Grace MJ, Biochim Biophys Acta 2005 1726 2 138 151 10.1016/j.bbagen.2005.06.006 16023295 (Pubitemid 41572253)
16. Development of a nasal adenovirus-based vaccine: Effect of concentration and formulation on adenovirus stability and infectious titer during actuation from two delivery devices. Renteria SS, Clemens CC, Croylea MA, Vaccine 2010 28 2137 2148 10.1016/j.vaccine.2009.12.025 20044048
17. Conglutinin acts as an opsonin for influenza A viruses. Hartshorn KL, Sastry K, Brown D, White MR, Okarma TB, Lee YM, J Immunol 1993 151 6265 73 8245465 (Pubitemid 23340372)
18. New approach to inter-technique comparisons for nanoparticle size measurements; using atomic force microscopy, nanoparticle tracking analysis and dynamic light scattering. Boyd RD, Pichaimuthu SK, Cuenat A, Colloid Surf A 2011 387 1-3 35 42
19. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Filipe V, Hawe A, Jiskoot W, Pharm Res 2010 27 5 796 810 10.1007/s11095-010-0073-2 20204471
20. ASTM E2834, Guide for Measurement of Particle Size Distribution of Nanomaterials in Suspension by Nanoparticle Tracking Analysis (NTA). Active Standard ASTM E2834 Developed by Subcommittee: E56.02 West Conshohocken, PA: ASTM International Book of Standards Volume: 14. 2012 02
21. Lah B, Eglon M, Banjac M, Strappe P, O'brien T, Strancar A, Peterka M, New chromatographic method on methacrylate monoliths used for adenoviral vectors purification Zadar: Croatian Microbiological Society Adenoviruses, Zadar, Croatia, 23-24 September, 2008. Adenoviruses: basic biology to gene therapy: book of abstracts. 2008 17
22. Peterka M, Strancar A, Banjac M, Kramberger P, Maurer E, Muster T, Method for influenza virus purification Netherlands: European Patent Office Rijswijk 2011 EP 2 361 975 A1
23. Standardized Viral Hemagglutination and Hemagglutination-Inhibition Tests. II. Description and Statistical Evaluation. Hierholzer JC, Suggs MT, Hall EC, Appl Microbiol 1969 18 5 824 833 4984203
24. Virology Methods Manual. Hierholzer JC, Killington RAB, San Diego: Academic Press, Mahy WJ, Kangro HO, 1996 41 43
25. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Guidance for Industry, Bioanalytical Method Validation 2001
26. Reproduction of Influenza viruses; Quantitative investigations with particle enumeration procedures on the dynamics of influenza A and B virus reproduction. Horsfall FL Jr, J Exp Med 1955 102 4 441 473 10.1084/jem.102.4.441 13263486
27. Kalbfuss B.,Wolff M.,Geisler L.,Tappe A.Wickramasinghe R.,Thom V.,Reichl U.Direct capture of influenza A virus from cell culture supernatant with Sartobind anion-exchange membrane adsorbers .Journal of Membrane Science 1:2 251-260 DOI 10.1016/j.memsci.2007.04.048.